


Teva Sues FDA Alleging Unlawful Interpretation of the Definition of “First Applicant”

Tribal Immunity Cannot Be Asserted to Escape IPR Proceedings

Now Available! Seyfarth Shaw’s BioLoquitur Bulletin: Drugs Available in 2018 for Generic Competition
FDA’s Office of Generic Drugs: 2017 Annual Report Highlights
Webinar: Bridging the Gap Between EU and U.S. Biotech Inventions Protection
Webinar: Biosimilar Litigation and Your BPCIA Compliance: Key Strategies In Light of AbbVie v. Boehringer

Now Available! Seyfarth Shaw’s Hatch-Waxman and Biosimilars Litigation: 2017 Year-in-Review
